Pharmacogenomics, lipid disorders, and treatment options

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 1, 2014, Pages 36-47

  Gryn, S E ^a   Hegele, R A ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIPOMERSEN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; KIDNEY FAILURE; MYALGIA; MYOPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION; TREATMENT RESPONSE;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84902781869     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.82     Document Type: Article

References (75)

1. Anderson, T.J. et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 29, 151-167 (2013)
2. Cholesterol Treatment Trialists Collaborators et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet 380, 581-590 (2012)
3. Ginsberg, H.N. The 2013 ACC/AHA guidelines on the treatment of blood cholesterol: questions, questions, questions. Circ. Res. 114, 761-764 (2014)
4. Wierzbicki, A.S., Viljoen, A., Hardman, T.C. & Mikhailidis, D.P. New therapies to reduce low-density lipoprotein cholesterol. Curr. Opin. Cardiol. 28, 452-457 (2013)
5. Baigent, C. et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181-2192 (2011)
6. The Accord Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010)
7. AIM-HIGH Investigators et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011)
8. Fu, J. et al. Western Database of Lipid Variants (WDLV): a catalogue of genetic variants in monogenic dyslipidemias. Can. J. Cardiol. 29, 934-939 (2013)
9. Gelissen, I.C. & McLachlan, A.J. The pharmacogenomics of statins. Pharmacol. Res. (2013); e-pub ahead of print 21 December 2013.
10. Hu, M. & Tomlinson, B. Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics 14, 981-995 (2013)
11. Patel, J., Abd, T., Blumenthal, R.S., Nasir, K. & Superko, H.R. Genetics and personalized medicine-A role in statin therapy? Curr. Atheroscler. Rep. 16, 384 (2014)
12. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011)
13. Tirona, R.G., Leake, B.F., Merino, G. & Kim, R.B. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-And African-Americans. J. Biol. Chem. 276, 35669-35675 (2001)
14. Akao, H. et al. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis 220, 413-417 (2012)
15. Chasman, D.I., Giulianini, F., MacFadyen, J., Barratt, B.J., Nyberg, F. & Ridker, P.M. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet. 5, 257-264 (2012)
16. Hopewell, J.C. et al.; MRC/BHF Heart Protection Study Collaborative Group. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur. Heart J. 34, 982-992 (2013)
17. Thompson, J.F. et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5, 352-358 (2005)
18. Couvert, P. et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9, 1217-1227 (2008)
19. Tomlinson, B. et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther. 87, 558-562 (2010)
20. Mega, J.L., Morrow, D.A., Brown, A., Cannon, C.P. & Sabatine, M.S. Identification of genetic variants associated with response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 29, 1310-1315 (2009)
21. Chasman, D.I., Posada, D., Subrahmanyan, L., Cook, N.R., Stanton, V.P. Jr & Ridker, P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821-2827 (2004)
22. Krauss, R.M. et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117, 1537-1544 (2008)
23. Shiffman, D. et al. Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS One 7, e38240 (2012)
24. Polisecki, E. et al.; Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigators. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 200, 109-114 (2008)
25. Polisecki, E. et al.; PROSPER Study Group. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis 200, 95-101 (2008)
26. Morrison, A.C. et al. Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am. J. Epidemiol. 166, 28-35 (2007)
27. Iakoubova, O.A. et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol. 51, 435-443 (2008)
28. Musunuru, K. Lack of association of KIF6 genotype with vascular disease and statin response. Circ. Cardiovasc. Genet. 4, 467-468 (2011)
29. Peng, P. et al. Meta-Analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect. PLoS One 7, e50126 (2012)
30. Charland, S.L. et al. Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. Pharmacogenomics J. (2013); e-pub ahead of print 27 August 2013.
31. Deshmukh, H.A. et al.; CARDS, ASCOT, and PROSPER Investigators. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) J. Lipid Res. 53, 1000-1011 (2012)
32. Thompson, J.F. et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ. Cardiovasc. Genet. 2, 173-181 (2009)
33. Barber, M.J. et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One 5, e9763 (2010)
34. Trompet, S. et al.; PROSPER Study Group. Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC Med. Genet. 12, 131 (2011)
35. Mancini, G.B. et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can. J. Cardiol. 29, 1553-1568 (2013)
36. Chowdhury, R. et al. Adherence to cardiovascular therapy: a metaanalysis of prevalence and clinical consequences. Eur. Heart J. 34, 2940-2948 (2013)
37. Wei, M.Y., Ito, M.K., Cohen, J.D., Brinton, E.A. & Jacobson, T.A. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J. Clin. Lipidol. 7, 472-483 (2013)
38. Needham, M. & Mastaglia, F.L. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul. Disord. 24, 4-15 (2014)
39. SEARCH Collaborative Group et al. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N. Engl. J. Med. 359, 789-799 (2008)
40. Voora, D. et al. The SLCO1B1*5 genetic variant is associated with statininduced side effects. J. Am. Coll. Cardiol. 54, 1609-1616 (2009)
41. Donnelly, L.A. et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther. 89, 210-216 (2011)
42. Brunham, L.R. et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12, 233-237 (2012)
43. de Keyser, C.E. et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet. Genomics 24, 43-51 (2014)
44. Danik, J.S., Chasman, D.I., MacFadyen, J.G., Nyberg, F., Barratt, B.J. & Ridker, P.M. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am. Heart J. 165, 1008-1014 (2013)
45. Wilke, R.A. et al.; Clinical Pharmacogenomics Implementation Consortium (CPIC) The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92, 112-117 (2012)
46. Becker, M.L. et al. Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J. 13, 251-256 (2013)
47. Oh, J., Ban, M.R., Miskie, B.A., Pollex, R.L. & Hegele, R.A. Genetic determinants of statin intolerance. Lipids Health Dis. 6, 7 (2007)
48. Ruano, G. et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis 218, 451-456 (2011)
49. Mangravite, L.M. et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502, 377-380 (2013)
50. Baker, S.K., Vladutiu, G.D., Peltier, W.L., Isackson, P.J. & Tarnopolsky, M.A. Metabolic myopathies discovered during investigations of statin myopathy. Can. J. Neurol. Sci. 35, 94-97 (2008)
51. Mohassel, P. & Mammen, A.L. The spectrum of statin myopathy. Curr. Opin. Rheumatol. 25, 747-752 (2013)
52. DeGorter, M.K. et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ. Cardiovasc. Genet. 6, 400-408 (2013)
53. Aslibekyan, S., Straka, R.J., Irvin, M.R., Claas, S.A. & Arnett, D.K. Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. Expert Rev. Cardiovasc. Ther. 11, 355-364 (2013)
54. Frazier-Wood, A.C. et al. The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. Pharmacogenomics J. 13, 312-317 (2013)
55. Aslibekyan, S. et al. Variants identified in a GWAS meta-Analysis for blood lipids are associated with the lipid response to fenofibrate. PLoS One 7, e48663 (2012)
56. Lai, C.Q. et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler. Thromb. Vasc. Biol. 27, 1417-1425 (2007)
57. Brautbar, A. et al. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. J. Lipid Res. 54, 1980-1987 (2013)
58. Hegele, R.A., Guy, J., Ban, M.R. & Wang, J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. 4, 16 (2005)
59. Simon, J.S. et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 86, 648-656 (2005)
60. Kim, D.S. et al. Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol. J. Lipid Res. 54, 1512-1520 (2013)
61. Berthold, H.K., Laaksonen, R., Lehtimaki, T., Gylling, H., Krone, W. & Gouni-Berthold, I. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-Absorption in response to ezetimibe treatment. Exp. Clin. Endocrinol. Diabetes 116, 262-267 (2008)
62. Shitara, Y., Hirano, M., Sato, H. & Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236 (2004)
63. Seithel, A. et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 35, 779-786 (2007)
64. Neuvonen, P.J., Niemi, M. & Backman, J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565-581 (2006)
65. Pang, J., Chan, D.C. & Watts, G.F. Critical review of non-statin treatments for dyslipoproteinemia. Expert Rev. Cardiovasc. Ther. 12, 359-371 (2014)
66. Thomas, G.S., Cromwell, W.C., Ali, S., Chin, W., Flaim, J.D. & Davidson, M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 62, 2178-2184 (2013)
67. Cuchel, M. et al.; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-Arm, open-label, phase 3 study. Lancet 381, 40-46 (2013)
68. Goldberg, A.S. & Hegele, R.A. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Des. Devel. Ther. 6, 251-259 (2012)
69. Lee, P. & Hegele, R.A. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert Opin. Investig. Drugs 22, 1411-1423 (2013)
70. Stein, E.A., Honarpour, N., Wasserman, S.M., Xu, F., Scott, R. & Raal, F.J. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128, 2113-2120 (2013)
71. Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92, 414-417 (2012)
72. Oswald, S. et al. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet. Genomics 18, 559-568 (2008)
73. Pisciotta, L. et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 194, e116-e122 (2007)
74. Wang, J., Williams, C.M. & Hegele, R.A. Compound heterozygosity for two nonsynonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin. Genet. 67, 175-177 (2005)
75. Miller, D.B. & Spence, J.D. Clinical pharmacokinetics of fibric acid derivatives (fibrates) Clin. Pharmacokinet. 34, 155-162 (1998)